Scinai Immunotherapeutics Ltd. (SCNI) Financial Analysis & Valuation | Quarter Chart
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with M... more
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $873,625 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Amir Reichman |
| IPO Date | 2015-05-11 | CAGR | — |
| Employees | 45 | Website | www.scinai.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SCNI chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $144.31M | P/E | -0.12 | Forward P/E | — | PEG | — |
| P/S | 0.01 | P/B | 0.01 | P/CF | -0.02 | P/FCF | -0.01 |
| Sales | $1.50M | Sales 1Y | 11.54% | Sales 3Y | inf% | Sales 5Y | inf% |
| EPS | $-14.23 | EPS 1Y | 4688.56% | EPS 3Y | -88.76% | EPS 5Y | -110.35% |
| Sales QoQ | -4.06% | EPS QoQ | -100% | Sales QoQ Avg | 11.5% | EPS QoQ Avg | 394714.08% |
| Gross Margin | -251.95% | Operating Margin | -562.79% | Profit Margin | -176.62% | ROCE | -56.36% |
| ROA | -15% | ROE | -27% | Altman Z Score | -11.68 | Piotroski Score | 3 |
| Current Ratio | 1.56 | Quick Ratio | 1.56 | Cash Ratio | 1.28 | Op. CF Ratio | -1.12 |
| Debt/Equity | 0.31 | Debt/Assets | 0.21 | Lt Debt/Equity | 0.27 | Lt Debt/Cap. | 0.02 |
| Intrst Cov. | -22.28 | Inventory Turnover | — | Asset Turnover | 0.09 | Receivables Turnover | 20.22 |
| Enterprise Value | $144.31M | P/E Ratio | -0.12 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.01 |
| EPS | $-14.23 | EPS Growth 1Y | 4688.56% |
| EPS Growth 3Y | -88.76% | EPS Growth 5Y | -110.35% |
| Revenue Growth 1Y | 11.54% | Gross Margin | -251.95% |
| Operating Margin | -562.79% | Profit Margin | -176.62% |
| ROE | -27% | ROA | -15% |
| ROCE | -56.36% | Current Ratio | 1.56 |
| Quick Ratio | 1.56 | Cash Ratio | 1.28 |
| Debt/Equity | 0.31 | Interest Coverage | -22.28 |
| Altman Z Score | -11.68 | Piotroski Score | 3 |
Scinai Immunotherapeutics Ltd. (SCNI) valuation & financials
Scinai Immunotherapeutics Ltd. (SCNI) has a market capitalization of $873,625 and trades at a price-to-earnings ratio of -0.1. It operates in the Healthcare sector (Biotechnology).
Scinai Immunotherapeutics Ltd.'s revenue grew +11.5% over the last year.
Scinai Immunotherapeutics Ltd.'s next earnings report is scheduled for December 2, 2026 before market open (provider scheduled date); analysts estimate EPS of $-8.50. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)